- Home
- FORA vs EPIX Comparison
FORA vs EPIX Comparison
Compare FORA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- EPIX
- Stock Information
- Founded
- FORA 2014
- EPIX 2009
- Country
- FORA United States
- EPIX Canada
- Employees
- FORA N/A
- EPIX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- EPIX Health Care
- Exchange
- FORA Nasdaq
- EPIX Nasdaq
- Market Cap
- FORA 62.7M
- EPIX 65.3M
- IPO Year
- FORA N/A
- EPIX N/A
- Fundamental
- Price
- FORA $1.99
- EPIX $1.70
- Analyst Decision
- FORA Strong Buy
- EPIX Hold
- Analyst Count
- FORA 1
- EPIX 3
- Target Price
- FORA $5.00
- EPIX $2.00
- AVG Volume (30 Days)
- FORA 27.4K
- EPIX 276.9K
- Earning Date
- FORA 05-16-2025
- EPIX 05-08-2025
- Dividend Yield
- FORA N/A
- EPIX N/A
- EPS Growth
- FORA N/A
- EPIX N/A
- EPS
- FORA N/A
- EPIX N/A
- Revenue
- FORA $20,153,263.00
- EPIX N/A
- Revenue This Year
- FORA $13.31
- EPIX N/A
- Revenue Next Year
- FORA N/A
- EPIX N/A
- P/E Ratio
- FORA N/A
- EPIX N/A
- Revenue Growth
- FORA N/A
- EPIX N/A
- 52 Week Low
- FORA $1.85
- EPIX $1.40
- 52 Week High
- FORA $4.03
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- FORA 49.09
- EPIX 56.90
- Support Level
- FORA $1.93
- EPIX $1.67
- Resistance Level
- FORA $2.11
- EPIX $1.79
- Average True Range (ATR)
- FORA 0.12
- EPIX 0.07
- MACD
- FORA 0.00
- EPIX -0.01
- Stochastic Oscillator
- FORA 34.75
- EPIX 38.30
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.